CA-PROVEN-SKINCARE
19.7.2022 10:07:07 CEST | Business Wire | Press release
PROVEN , the expert in personalized skincare, today announced its international expansion into the European Union and the United Kingdom. Products are currently available to purchase. This is PROVEN’s first international expansion since it launched in Canada in July 2021. The PROVEN team made the decision to expand across the Atlantic due to the global demand for personalized skincare solutions. This expansion comes after a period of extraordinary growth for the company, which includes the launch of its first new product since 2019, the Eye Cream Duo, and having been granted a groundbreaking patent that protects PROVEN’s use of personalization in skincare.
Since its founding in 2017 and launch in 2019, PROVEN Skincare has grown rapidly to become the leading skincare personalization brand. The company has launched five products personalized to customers’ unique needs, received the 2018 MIT Artificial Intelligence Technology Award, was awarded Best Use of Technology at the 2022 Glossy Beauty Awards for its proprietary Skin Genome Project™, and reached more than $30 million in revenue in just three years.
“I am incredibly proud to bring PROVEN’s personalized, data and AI-backed products to the people of the European Union and the United Kingdom,” said PROVEN co-founder and CEO Ming S. Zhao . “Too many consumers still rely on one-size-fits-all skincare products that do not take into account their unique concerns and needs. PROVEN provides personalized, adaptive, effective skincare solutions that take into account a person's skin, life, and environment. The entire PROVEN team is thrilled to enter these new markets and provide people with skincare solutions as unique as they are.”
In order to provide personalized skincare to customers across the European Union and the United Kingdom, the PROVEN team gathered extensive environmental data about the region and executed a major tech build to incorporate it into PROVEN's existing AI. Integrating local environmental conditions into the skincare formulas is essential for effective skincare products.
PROVEN was founded in 2017 by Ming Zhao and Dr. Amy Yuan and launched in 2019. Ming was in the midst of a career in private equity, working long hours when she began to notice the quality of her skin was suffering. She embarked on a personal mission to find products to solve her problems but found that most were expensive, didn’t work consistently, and the trial and error of trying to find something that worked was time-consuming.
She brought this up with her friend Amy, who just so happened to be a Computational Physicist at Stanford, who was having her own skin challenges. Recognizing that the beauty industry lacked a brand that offered personalized and effective solutions, the two joined forces to create a holistic, personalized approach to skincare that is completely backed by data. The result was PROVEN, which harnesses the power of big data and AI to create personalized skincare products.
PROVEN creates simple, personalized, and clinically proven skincare products at scale thanks to its proprietary Skin Genome Project ™ — the largest beauty database on earth. The Skin Genome Project™ takes the following data into account in order to craft personalized products for consumers:
- The effectiveness of over 20,238 skincare ingredients.
- Information about over 100,000 individual products (luxury, prescription, generic, etc.).
- Over 20 million testimonials from real people.
- Over 4,000 scientific publications.
- The water hardness, humidity level, and UV index where you live.
PROVEN currently offers five products personalized to customers’ unique needs. The products include Personalized Cleaner, Personalized Day Moisturizer, Personalized Night Cream, Personalized Day Eye Cream, and Personalized Night Eye Cream. The products can be conveniently purchased as systems or purchased separately.
PROVEN has only been available in the United States and Canada until this expansion.
About PROVEN
PROVEN is a technology company that harnesses the power of big data and AI to create personalized skincare products. At PROVEN we are building a global self-care movement based on technology and personalization. Through our proprietary Skin Genome Project™ — the largest beauty database on earth — we’ve analyzed over 25 million consumer testimonials and 4,000 skin-related scientific papers to create simple, personalized, and clinically-proven skincare products. PROVEN is a Y Combinator alum and 2018 MIT AI Technology Award recipient. Learn more at www.provenskincare.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005333/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Cessna Caravans to Boost USDA’s Fight Against Crop-Damaging Insects12.5.2026 17:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced that the U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) has ordered three Cessna Caravan aircraft to support its sterile insect release program protecting citrus crops along the Rio Grande River in southern Texas. The new aircraft are expected to be delivered in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512676348/en/ Mission-Ready: The Cessna Caravan joins USDA’s fight to protect Texas citrus from invasive pests APHIS will use the Caravans to carry and release sterile insects that help prevent the spread of destructive pests, including fruit flies. The environmentally friendly technique helps safeguard fruit-bearing trees, reduce crop damage and protect agricultural industries that rely on healthy harvests. “These aircraft will help APHIS reach remote areas and carry out their important mission o
Elliptic Secures $120 Million Investment From Nasdaq Ventures, Deutsche Bank, One Peak and the British Business Bank12.5.2026 16:05:00 CEST | Press release
The institutions building the future of finance are choosing Elliptic as the standard on-chain analytics for digital assets Elliptic, the global leader in digital asset decisioning, today announced the closing of a $120 million Series D fundraise led by One Peak, with participation from Nasdaq Ventures, Deutsche Bank and the British Business Bank. The round values Elliptic at $670 million. These investors are among the most consequential institutions in global finance, together responsible for trillions in daily market activity, and they have placed their confidence in Elliptic. It is a signal about where the financial system is heading and who is trusted to underpin it, with Elliptic screening more of the global on-chain economy than any other private sector provider. The fundraise will accelerate Elliptic's mission to deliver the enterprise-grade on-chain analytics for the world's largest and most demanding banks, fintechs, government agencies and crypto and payments companies in the
Rigaku Accelerates Next-generation Semiconductor Metrology Development Leveraging World-Class Research Infrastructure12.5.2026 16:00:00 CEST | Press release
Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced the expansion of its development of metrology technologies for next-generation semiconductors, leveraging global research environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512888328/en/ Signing ceremony with imec held on April 9 As part of this initiative, Rigaku is working with imec, a world-leading semiconductor research and innovation hub headquartered in Belgium, under a three-year development program. Through this effort, Rigaku will advance its core X-ray technologies, including 3D device metrology, high-sensitivity detection of ultrathin films and trace elements, and non-destructive inspection of microscopic defects. As semiconductor devices evolve toward advanced architectures such as Gate-All-Around (GAA) and
Aster Guardians Global Nursing Award Announces Top 10 Finalists for 202612.5.2026 15:54:00 CEST | Press release
On the occasion of International Nurses Day, Aster DM Healthcare has announced the Top 10 finalists for the fifth edition of the Aster Guardians Global Nursing Award 2026, selected from over 134,000 registrations across 214* countries and economies. One of the Top 10 finalists will be honoured with the grand title and a prize of USD 250,000. Aster has appointed Ernst & Young LLP as the 'Process Advisors' of the award. EY has defined a three-stage evaluation process to determine the finalists and the winner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512872373/en/ Aster Guardians Global Nursing Awards 2026 - Top 10 Finalists (Photo: AETOSWire) The top 10 finalists for 2026 includes: Dr. Agimol Pradeep (United Kingdom), Dr. Aidah Alkaissi (Sweden), Dinah Sevilla (The Kingdom of Saudi Arabia), Dr. Hammoda Abu-Odah (Hong Kong SAR, China), Hindumbi Kaurom Kakkada (India), Johana Patricia Galvan Barrios (Colombia), Josephin
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress12.5.2026 15:30:00 CEST | Press release
Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious Plenary Abstracts SessionOral and poster presentations to feature new data for INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with myeloproliferative neoplasms (MPNs) Incyte (Nasdaq:INCY) today announced that data from key programs in its Hematology and Oncology franchises will be presented at the European Hematology Association (EHA) 2026 Congress, to be held June 11 - 14, 2026, in Stockholm, Sweden. “The breadth of the data that will be showcased at the 2026 EHA Congress highlights the continued advancement of our Hematology and Oncology pipeline and our focus on delivering differentiated medicines for patients with cancer and hematologic diseases,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “These presentations include findings fro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
